AFMD
Affimed NVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.98M
P/E Ratio
—
EPS
$-5.09
Beta
2.07
52W High
$1.13
52W Low
$0.07
50-Day MA
$0.50
200-Day MA
$1.76
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Affimed NV
Affimed NV, a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The company is headquartered in Heidelberg, Germany.
Fundamentals
| Revenue (TTM) | $5.64M |
| Gross Profit (TTM) | $5.64M |
| EBITDA | $-60.76M |
| Operating Margin | -8709.00% |
| Return on Equity | -149.50% |
| Return on Assets | -49.40% |
| Revenue/Share (TTM) | $0.37 |
| Book Value | $1.05 |
| Price-to-Book | 0.06 |
| Price-to-Sales (TTM) | 0.53 |
| EV/Revenue | 13.07 |
| EV/EBITDA | 1.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -91.60% |
| Shares Outstanding | $16.39M |
| Float | $15.48M |
| % Insiders | 6.01% |
| % Institutions | 19.89% |
Data last updated: 4/7/2026